Literature DB >> 19607947

Immunoprophylaxis in asplenic patients.

D P Harji1, S S Jaunoo, P Mistry, P N Nesargikar.   

Abstract

The asplenic patient is at risk of overwhelming post-splenectomy infection (OPSI) due to encapsulated bacteria, namely pneumococcus, haemophilus influenza B and meningococcal C pathogens. The lifetime risk is 1-2% with the estimated mortality being in the region of 40-70% (Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 2001;7:657-60). Preventative measures include appropriate prophylactic vaccination, long term antibiotics and patient education. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen were first published by the British Committee for Standards in Haematology in 1996, with a revised edition published in 2002. There are a number of permutations of these guidelines published by a number of professional bodies and consequently this has led to variable adherence rates to such guidelines. We review the perioperative administration of prophylactic vaccinations.

Entities:  

Mesh:

Year:  2009        PMID: 19607947     DOI: 10.1016/j.ijsu.2009.07.003

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  3 in total

1.  Unusual presentation of Streptococcus pneumoniae-induced septic shock 36 years after splenectomy.

Authors:  P Scheiermann; I Rösch; A G Nerlich; R Huf; S N Kunz; F Janner; F Weis; O Peschel
Journal:  Infection       Date:  2011-03-20       Impact factor: 3.553

Review 2.  Splenectomy and distal pancreatectomy in advanced ovarian cancer.

Authors:  Eun Ji Lee; Soo Jin Park; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

Review 3.  Recommended vaccinations for asplenic and hyposplenic adult patients.

Authors:  Paolo Bonanni; Maddalena Grazzini; Giuditta Niccolai; Diana Paolini; Ornella Varone; Alessandro Bartoloni; Filippo Bartalesi; Maria Grazia Santini; Simonetta Baretti; Carlo Bonito; Paola Zini; Maria Teresa Mechi; Fabrizio Niccolini; Lea Magistri; Maria Beatrice Pulci; Sara Boccalini; Angela Bechini
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.